1. Home
  2. FNWD vs CHRS Comparison

FNWD vs CHRS Comparison

Compare FNWD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finward Bancorp

FNWD

Finward Bancorp

HOLD

Current Price

$42.49

Market Cap

187.1M

Sector

Finance

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.04

Market Cap

159.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWD
CHRS
Founded
1994
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.1M
159.1M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
FNWD
CHRS
Price
$42.49
$1.04
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
7.0K
★ 1.4M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 1.14%
N/A
EPS Growth
N/A
★ 472.00
EPS
★ 1.00
N/A
Revenue
N/A
N/A
Revenue This Year
$10.81
$44.19
Revenue Next Year
$5.26
$65.06
P/E Ratio
$42.13
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$30.05
$0.94
52 Week High
$45.90
$2.62

Technical Indicators

Market Signals
Indicator
FNWD
CHRS
Relative Strength Index (RSI) 60.29 42.70
Support Level $42.56 $0.97
Resistance Level $44.01 $1.53
Average True Range (ATR) 0.79 0.07
MACD 0.20 0.00
Stochastic Oscillator 100.00 46.68

Price Performance

Historical Comparison
FNWD
CHRS

About FNWD Finward Bancorp

Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: